isembyld

Scholar Rock Receives FDA Approval for Isembyld as the First Myostatin-Targeted Therapy for Spinal Muscular Atrophy

In a landmark decision for the rare disease community, the U.S. Food and Drug Administration (FDA) granted approval on Friday…